Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 14/20 | 0.86 |
| ▸ | ABL1 | P00519 | 12/20 | 0.86 |
| ▸ | BCR | P11274 | 8/20 | 0.86 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.86 |
| ▸ | EGFR | P00533 | 1/20 | 0.84 |
| ▸ | PRKCA | P17252 | 1/20 | 0.84 |
| ▸ | KIT | P10721 | 5/20 | 0.79 |
| ▸ | KDR | P35968 | 2/20 | 0.74 |
| ▸ | ABL2 | P42684 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9820 | 0.93 | PDGFRA (1.00) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL3055349 | 0.92 | PDGFRA (0.89) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL13498211 | 0.92 | PDGFRA (0.88) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL29498750 | 0.92 | PDGFRA (1.00) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL9782 | 0.92 | PDGFRA (1.00) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL11932096 | 0.91 | PDGFRA (0.86) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL11927842 | 0.91 | ABL1 (1.00) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL4803395 | 0.91 | PDGFRA (0.87) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL9677 | 0.91 | PDGFRA (1.00) | PDGFRAABL1BCRPDGFRBEGFR | |
| Methane SCHEMBL5972158 | 0.91 | PDGFRA (0.98) | PDGFRAABL1BCRPDGFRBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | MDM2, XIAP, ADRM1 | PDGFRA 3541/4885ABL1 508/4885BCR 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.